Rocket Pharmaceuticals to Acquire Gene Therapy Developer Renovacor
Rocket Pharmaceuticals is expanding its reach into gene therapies with the purchase of Massachusetts-based Renovacor in a deal valued at approximately $53 million.
Renovacor is focused on developing therapies for a severe form of heart failure, BAG3-associated dilated cardiomyopathy.
Rocket CEO Gaurav Shah said the company plans to combine Renovacor’s preclinical work with its own clinical, regulatory and manufacturing expertise, to develop gene therapies that offer “the best chance for success to these patients.”
The acquisition deal is expected to close by the first quarter of 2023.